Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Advanced Solid Tumor
Clinical trial register · China

Advanced Solid Tumor Trials in China, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19187 matching records held by the registry are in this view. Synced 08 Nov 2026, 03:17 UTC
19187
Studies in scope
all four open statuses
11790
Recruiting now
open to new participants
2028
Lead sponsors
across recruiting studies
Top sites
Beijing 62 Shanghai 52 Guangzhou 39 Hangzhou 20 Changsha 18
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
BeOne Medicines11 Cancer Institute and Hospital, Chinese Academy of Medical Sciences5 LaNova Medicines Limited4 Suzhou Zelgen Biopharmaceuticals Co.,Ltd4 Daiichi Sankyo4
Site location
Beijing62 Shanghai52 Guangzhou39 Hangzhou20 Changsha18
All 67 locations
Target enrolment
to

Advanced Solid Tumor trials in China

153 of 19187 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 1
27
Beijing
2026-11-01
Not yet open
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 1/2
348
Shanghai
2026-11
Recruiting
Beijing Sungen Biomedical Technology Co., Ltd
Phase 1/2
332
Beijing
2026-08-17
Recruiting
LaNova Medicines Limited
Phase 2
108
Beijing
2026-07-29
Recruiting
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 1/2
551
Beijing, Jinan
2026-07-03
Not yet open
A Clinical Study of ZL-85FA Tablets
NCT07339748Advanced Solid Tumor
Chengdu Zenitar Biomedical Technology Co., Ltd
Phase 1/2
51
Hefei
2026-06-30
Recruiting
Nanjing Immunophage Biotech Co., Ltd
Phase 1/2
52
Shanghai
2026-06-16
Not yet open
Biotech Pharmaceutical Co., Ltd.
Phase 1
60
Chongqing, Zhengzhou, Changsha, Nanjing, Xi'an, Shanghai, Taiyuan, Chengdu
2026-05-30
Recruiting
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 1/2
178
Beijing, Harbin, Tianjin
2026-05-27
Recruiting
Personalized Neoantigen-pulsed Autologous Dendritic Cell Injections for Malignant Solid Tumors
NCT07752953Advanced Solid Tumor, Cancer, Malignant Solid Tumor
ZSky Biotech Inc
Not applicable
100
Qinhuangdao
2026-05-01
Recruiting
BeOne Medicines
Phase 1
84
Beijing, Chongqing, Fuzhou, Guangzhou, Yichang, Shanghai
2026-04-13
Recruiting
Shanghai Mabgen Biopharmaceutical Technology Co., Ltd.
Phase 1
116
Beijing, Chengdu
2026-03-18
Recruiting
Jiangsu HengRui Medicine Co., Ltd.
Phase 1
200
Hangzhou
2026-03-12
Recruiting
A Study of PLB-002 in Advanced Solid Tumors
NCT07304128Advanced Solid Tumor
Primelink BioTherapeitics(ShenZhen) Limited
Phase 1
100
Shanghai
2026-02-06
Recruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 1
27
Langfang
2026-01-29
Recruiting
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 1/2
198
Shanghai
2026-01-07
Recruiting
BeOne Medicines
Phase 1
86
Beijing, Chongqing, Xiamen, Guangzhou, Harbin, Changsha, Nanjing, Shanghai
2025-12-11
Recruiting
BeOne Medicines
Phase 1
105
Beijing, Guangzhou, Harbin, Wuhan, Nanjing, Jinan, Weifang
2025-12-11
Recruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Early Phase 1
36
Beijing
2025-11-27
Recruiting
BeOne Medicines
Phase 1
63
Beijing, Chongqing, Xiamen, Harbin, Zhengzhou, Shanghai, Chengdu, Hangzhou
2025-11-10
Recruiting
Qilu Pharmaceutical Co., Ltd.
Phase 1/2
444
Shanghai
2025-10-24
Recruiting
JMT106 Injection in the Treatment of Advanced Solid Tumors
NCT07275073Advanced Solid Tumor, Lung Squamous Cell Carcinoma, Hepatocellular Carcinoma
Shanghai JMT-Bio Inc.
Phase 1
200
Zhejiang
2025-09-25
Recruiting
VSV-02 Compassionate Use in Advanced Solid Tumors
NCT07260591Advanced Solid Tumor, Melanoma, Breast Cancer, Lung Cancer
The First Affiliated Hospital of Xinxiang Medical College
Phase 1
6
Xinxiang
2025-09-22
Recruiting
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1/2
424
Harbin, Shanghai, Hangzhou
2025-09-22
Recruiting
LaNova Medicines Limited
Phase 1/2
320
Shanghai
2025-09-17
Not yet open
Convalife (Shanghai) Co., Ltd.
Phase 1/2
318
Guangzhou
2025-09-10
Not yet open
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 1/2
153
Beijing
2025-09
Recruiting
BioNTech SE
Phase 1/2
375
Beijing, Hefei, Henan, Hunan, Shandong, Shanghai, Sichuan, Zhejiang
2025-08-27
Recruiting
A Study of PEP08 in Patients With MTAP-Del Advanced or Metastatic Solid Tumors
NCT06973863Advanced Solid Tumor, Solid Tumors, MTAP-deleted Solid Tumors, MTAP Deletion
PharmaEngine
Phase 1
40
2025-08-26
Recruiting
BioNTech SE
Phase 1/2
1,438
Chongqing, Hangzhou, Tianjin, Wuhan
2025-08-12
Recruiting
OBI Pharma, Inc
Phase 1/2
147
2025-08-04
Recruiting
China-Japan Friendship Hospital
Phase 1/2
38
Beijing
2025-08-01
Recruiting
Sichuan Huiyu Pharmaceutical Co., Ltd
Phase 1/2
262
Beijing
2025-07-22
Recruiting
Wigen Biomedicine Technology (Shanghai) Co., Ltd.
Phase 1/2
86
Beijing, Fuzhou, Guangzhou, Nanning, Wuhan, Changsha, Shenyang, Hangzhou
2025-07-10
Recruiting
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1
630
Beijing, Guangzhou, Harbin, Nanchang, Shenyang, Jinan, Shanghai, Tianjin
2025-07-02
Recruiting
Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
Phase 1
36
Nanjing, Beijing, Shanghai
2025-06-18
Active, closed
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 2
50
Guangzhou
2025-06-13
Active, closed
Guangdong Hengrui Pharmaceutical Co., Ltd
Phase 1
15
Fuzhou, Changsha
2025-06-09
Not yet open
Shouyao Holdings (Beijing) Co. LTD
Phase 1/2
102
Beijing
2025-06
Recruiting
Hansoh BioMedical R&D Company
Phase 1
502
Shanghai
2025-05-29
Recruiting
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 1/2
60
Guangzhou
2025-05-20
Recruiting
Qilu Pharmaceutical Co., Ltd.
Phase 1/2
149
Guangzhou
2025-05-09
Recruiting
a Polyphenol Whole Tumor Cell Vaccine in Patients With Advanced Malignant Solid Tumors
NCT06878612Polyphenols, Cancer Vaccine, Advanced Solid Tumor
Xingchen Peng
Phase 1
9
Chengdu
2025-04-21
Recruiting
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 1/2
194
Hefei, Beijing, Fuzhou, Lanzhou, Wuwei, Shenzhen, Nanning, Tangshan
2025-04-08
Recruiting
FBD Biologics Limited
Phase 1
50
Hangzhou, Xuzhou, Yantai, Zhujiang
2025-04-02
Recruiting
Coherus Oncology, Inc.
Phase 1
154
2025-04-01
Not yet open
LaNova Medicines Limited
Phase 2
84
Beijing
2025-03-26
Recruiting
A Study of BGB-B455 in Adults With Advanced or Metastatic Solid Tumors
NCT06803680Advanced Solid Tumor, Metastatic Solid Tumor
BeOne Medicines
Phase 1
90
Beijing, Nanchang, Shanghai, Taiyuan
2025-03-18
Recruiting
A Phase I Trial of Tumor-Associated Lymph Node T-Cell Injection With Advanced Malignant Solid Tumors
NCT06716619Tumor Associated Lymph Node T Cell, Advanced Solid Tumor, Immunotherapy, Serplulimab Injection
DrugSerplulimab
Guangzhou FineImmune Biotechnology Co., LTD.
Phase 1
32
Guangzhou
2025-02-13
Recruiting
BeOne Medicines
Phase 1
695
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Meizhou, Nanning
2025-01-10
Recruiting
Changchun GeneScience Pharmaceutical Co., Ltd.
Phase 1
163
Beijing, Zhengzhou, Changsha, Nanjing, Jinan, Shanghai, Tianjin
2025-01-08
Active, closed
Daiichi Sankyo
Phase 2
335
Changsha, Shanghai
2025-01-06
Recruiting
Study of ISM6331 in Participants With Advanced/Metastatic Mesothelioma or Other Advanced Solid Tumors
NCT06566079Malignant Mesothelioma, Metastatic Malignant Solid Tumor, Advanced Solid Tumor
InSilico Medicine Hong Kong Limited
Phase 1/2
160
Zhengzhou, Shanghai, Beijing, Guangzhou
2024-12-27
Recruiting
APG-2449 Monotherapy or in Combination With PLD in Patients With Platinum-resistant Recurrent OC or Advanced ST
NCT06687070Platinum-resistant Recurrent Ovarian Cancer, Advanced Solid Tumor
DrugAPG -2449
Ascentage Pharma Group Inc.
Phase 1
90
Guangzhou
2024-12-17
Recruiting
BeOne Medicines
Phase 1
168
Bengbu, Hefei, Beijing, Fuzhou, Xiamen, Nanning, Shijiazhuang, Harbin
2024-12-09
Recruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
15
Beijing
2024-11-25
Recruiting
Jacobio Pharmaceuticals Co., Ltd.
Phase 1/2
334
Hefei, Beijing, Fuzhou, Guangzhou, Nanning, Langfang, Haerbin, Zhengzhou
2024-11-22
Recruiting
Innolake Biopharm
Phase 1
240
Shanghai
2024-10-30
Recruiting
BeOne Medicines
Phase 1
153
Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Shijiazhuang, Harbin, Wuhan
2024-10-18
Recruiting
Xiaorong Sun
Phase 1
20
Jinan
2024-10-14
Active, closed
The First Affiliated Hospital with Nanjing Medical University
Phase 2
35
Nanjing
2024-10-09
Recruiting
Study of AXT-1003 in Subjects With Advanced Malignant Tumors.
NCT06484985Non-Hodgkin Lymphoma, Advanced Solid Tumor
Axter Therapeutics (Beijing) Co., Ltd
Phase 1
78
Beijing, Changsha, Fuzhou, Guangzhou, Shanghai
2024-09-04
Recruiting
The Affiliated Hospital Of Guizhou Medical University
Early Phase 1
40
Guiyang
2024-08-29
Recruiting
CSPC Megalith Biopharmaceutical Co.,Ltd.
Phase 1
400
Harbin, Shanghai
2024-08-15
Recruiting
Shanghai Pharmaceuticals Holding Co., Ltd
Phase 1
170
Changsha, Fuzhou, Hangzhou, Kunming, Shanghai, Wuhan
2024-08-06
Recruiting
Shanghai Institute Of Biological Products
Phase 1
196
Beijing
2024-07-23
Recruiting
TGRX-1942 Chinese Phase I for Advanced Solid Tumor And/or Relapsed/Refractory Hematologic Malignancies
NCT06484816Non Small Cell Lung Cancer, Advanced Solid Tumor, Hematologic Malignancy
Shenzhen TargetRx Co., Ltd.
Phase 1
90
Hangzhou
2024-07-08
Recruiting
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
NCT06465069Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor, Urinary Bladder Neoplasm
DrugPembrolizumab
Eli Lilly and Company
Phase 1
460
Beijing, Guangzhou, Shanghai
2024-07-01
Not yet open
Qilu Pharmaceutical Co., Ltd.
Phase 2
360
Beijing
2024-06-30
Recruiting
Latticon Antibody Therapeutics, Inc
Phase 1/2
150
Jinan, Hangzhou
2024-06-05
Recruiting
Shanghai Institute Of Biological Products
Phase 1
144
Shanghai
2024-05-09
Recruiting
Chengdu Zenitar Biomedical Technology Co., Ltd
Phase 1/2
132
Guanzhou, Chengdu
2024-05-08
Active, closed
A Machine Learning-based Estimated Survival Model
NCT06432283Advanced Solid Tumor
Zhao Siyao
Observational
1,000
Chengdu
2024-05-01
Recruiting
Hansoh BioMedical R&D Company
Phase 1
610
Shanghai
2024-04-26
Active, closed
A Study of MHB039A for Advanced Solid Tumor
NCT06345482Advanced Solid Tumor
DrugMHB039A
Minghui Pharmaceutical (Hangzhou) Ltd
Phase 1/2
196
Shanghai
2024-04-16
Recruiting
BeOne Medicines
Phase 1
308
Beijing, Fuzhou, Guangzhou, Harbin, Wuhan, Dalian, Shenyang, Jinan
2024-04-12
Active, closed
D2M Biotherapeutics Inc.
Phase 1
160
Beijing
2024-04-09
Recruiting
Beijing Xunsheng Biomedical Research Co., Ltd.
Phase 1
15
Beijing
2024-04-08
Recruiting
HC Biopharma Inc.
Phase 1
122
Guangzhou
2024-03-27
Recruiting
PharmaEngine
Phase 1
54
2024-03-27
Recruiting
Luye Pharma Group Ltd.
Phase 1
102
Beijing
2024-03-12
Recruiting
NovaRock Biotherapeutics, Ltd
Phase 1
270
Shijiazhuang
2024-03-08
Active, closed
A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors
NCT06238479Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor, Urinary Bladder Neoplasm
Eli Lilly and Company
Phase 1
490
Beijing, Changsha, Shanghai
2024-03-05
Recruiting
HC Biopharma Inc.
Phase 1
76
Shanghai
2024-02-27
Recruiting
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
NCT06172478Advanced Solid Tumor, Melanoma, Head and Neck Cancer, Gastric Cancer
DrugPatritumab deruxtecan
Daiichi Sankyo
Phase 2
740
Chengdu, Guangzhou
2024-02-26
Active, closed
Daiichi Sankyo
Phase 1
210
Beijing, Guangzhou, Heilongjiang, Hunan, Jilin City, Shandong
2024-02-22
Recruiting
Hansoh BioMedical R&D Company
Phase 2
220
Hefei, Fujian, Fuzhou, Guangzhou, Harbin, Anyang, Luoyang, Nanyang
2024-02-06
By invitation
Shenzhen NewDEL Biotech, Co., Ltd
Phase 1
96
Xiamen, Lanzhou, Guangzhou, Shenzhen, Zhanjiang, Nanning, Guiyang, Wu’an
2024-02-04
Recruiting
Study SC-101 in Subjects With Advanced Malignancies
NCT06220838Advanced Solid Tumor
Tianjin ConjuStar Biologics Co., Ltd.
Phase 1
100
Beijing, Changsha, Nanjing, Shanghai, Tianjin
2024-02-02
Not yet open
Shanghai Runshi Pharmaceutical Technology Co., Ltd
Phase 1/2
168
Beijing
2024-01-30
Recruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 1
60
Beijing
2024-01-24
Recruiting
Chipscreen Biosciences, Ltd.
Phase 1
196
Guangzhou
2024-01-05
Recruiting
Sichuan University
Phase 1
29
Chengdu
2024-01-01
Recruiting
Peking University
Phase 1
20
Beijing
2024-01-01
Recruiting
Xinlu Wang
Phase 1
20
Guangzhou
2024-01
Recruiting
Ruimin Wang
Phase 1
20
Beijing
2024-01
Recruiting
Hunan Province Tumor Hospital
Phase 1/2
430
Changsha
2023-12-25
Recruiting
Ruijin Hospital
Early Phase 1
34
Shanghai
2023-12-20
Recruiting
Eikon Therapeutics
Phase 1/2
156
Guangzhou, Shijiazhuang, Jinan, Hangzhou, Chongqing, Fuzhou, Shanghai
2023-12-11
Recruiting
BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
NCT06120283Advanced Solid Tumor, Advanced Breast Cancer, Metastatic Breast Cancer, Hormone-receptor-positive Breast Cancer
DrugsBGB-43395·Elacestrant·Letrozole·Fulvestrant
BeOne Medicines
Phase 1
433
Beijing, Fuzhou, Guangzhou, Harbin, Nanchang, Shenyang, Shanghai
2023-12-01
Recruiting
TaiRx, Inc.
Phase 1
30
2023-10-31
Recruiting
Shanghai Yuyao Biotech Co., Ltd.
Phase 1
96
Shanghai
2023-10-26
Active, closed
Broadenbio Ltd., Co.
Phase 1
42
Beijing
2023-10-26
Recruiting
FBD Biologics Limited
Phase 1
80
Hangzhou
2023-10-02
Recruiting
Shanghai East Hospital
Phase 1
24
Shanghai
2023-10
Active, closed
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1/2
990
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Dongguan, Foshan, Guangzhou
2023-09-22
Recruiting
BeOne Medicines
Phase 1
337
Hefei, Harbin, Wuhan, Shenyang, Jining, Yantai, Shanghai, Chengdu
2023-09-21
Active, closed
Mabwell (Shanghai) Bioscience Co., Ltd.
Phase 1/2
261
Shanghai
2023-08-28
Recruiting
The Fourth Affiliated Hospital of Zhejiang University School of Medicine
Phase 1/2
183
Yiwu
2023-08-23
Recruiting
First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors
NCT05875168Advanced Solid Tumor, Metastatic Solid Tumor
DrugDS-3939a
Daiichi Sankyo
Phase 1/2
590
Beijing, Changchun, Changsha, Chengdu, Hangzhou, Jinan, Nanchang, Neijiang
2023-08-18
Recruiting
DualityBio Inc.
Phase 1/2
1,000
Zhengzhou, Changsha, Nanjing, Wuxi, Changchun, Shenyang, Shanghai, Chengdu
2023-08-17
Recruiting
Shandong Boan Biotechnology Co., Ltd
Phase 1
78
Beijing
2023-08-16
Active, closed
Beijing Biostar Pharmaceuticals Co., Ltd.
Phase 1/2
84
Beijing, Chengdu, Guangzhou, Jinan, Shanghai, Shenyang, Shijiazhuang, Wuhan
2023-06-09
Recruiting
Phase I Clinical Study of Tumor-associated Lymph Node T Cell Therapy for Advanced Solid Tumors
NCT06302062Advanced Solid Tumor, Tumor Associated Lymph Node T Cell, Immunotherapy
DrugsAldesleukin·Serplulimab·Cyclophosphamide
Guangzhou FineImmune Biotechnology Co., LTD.
Phase 1
23
Guangzhou
2023-06-06
Active, closed
A Study of MHB036C for Advanced Solid Tumor
NCT06373406Advanced Solid Tumor
DrugMHB036C
Minghui Pharmaceutical (Hangzhou) Ltd
Phase 1/2
200
Shanghai
2023-05-26
Recruiting
Shanghai Hengrui Pharmaceutical Co., Ltd.
Phase 1
174
Hangzhou
2023-05-18
Recruiting
Betta Pharmaceuticals Co., Ltd.
Phase 1
82
Beijing, Baoding, Harbin, Wuhan, Changsha, Changchun, Jinan, Taizhou
2023-04-24
Recruiting
Guangzhou Sinogen Pharmaceutical Co., Ltd
Phase 1/2
70
Guangzhou, Chengdu
2023-04-19
Active, closed
Regor Pharmaceuticals Inc.
Phase 1
40
Shanghai
2023-04-17
Recruiting
A Study of TIL in Advanced Solid Tumors (DFGD)
NCT06488950Advanced Solid Tumor, Tumor Infiltrating Lymphocytes, Treatment Side Effects, Effects of Immunotherapy
DrugEngineering Tumor Infiltrating Lymphocytes
Shanghai Juncell Therapeutics
Early Phase 1
30
Shanghai
2023-04-01
Not yet open
Xuanzhu Biopharmaceutical Co., Ltd.
Phase 1
38
Beijing
2023-04
Recruiting
A Study of XZB-0004 in Patients With Solid Tumors
NCT05772455Advanced Solid Tumor, NSCLC
Xuanzhu Biopharmaceutical Co., Ltd.
Phase 1
128
Shanghai
2023-03-24
Active, closed
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Phase 1/2
725
Beijing, Changsha, Fuzhou, Guangzhou, Hangzhou, Ha’erbin, Hefei, Jinan
2023-03-15
Recruiting
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Phase 1
248
Shanghai
2023-03-02
Recruiting
Guangzhou Sinogen Pharmaceutical Co., Ltd
Phase 1/2
70
Guangzhou, Harbin, Changsha, Shanghai, Chengdu
2023-01-16
Recruiting
TR64 in Patients With Advanced Solid Tumors
NCT05649345Advanced Solid Tumor
Tarapeutics Science Inc.
Phase 1
19
Bengbu, Shenyang
2023-01-12
Recruiting
Broadenbio Ltd., Co.
Phase 1
78
Guangzhou, Zhengzhou
2022-12-29
Recruiting
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 1/2
222
Beijing
2022-11-15
Active, closed
Shanghai East Hospital
Phase 1
36
Shanghai
2022-09-14
Recruiting
Betta Pharmaceuticals Co., Ltd.
Phase 1
110
Chaoyang, Cangzhou, Tianjin
2022-08-29
Active, closed
LaNova Medicines Limited
Phase 1/2
392
Beijing
2022-08-26
Recruiting
Shanghai Huaota Biopharmaceutical Co., Ltd.
Phase 1/2
80
Jinan
2022-08-25
Recruiting
Jiangsu Aosaikang Pharmaceutical Co., Ltd.
Phase 1
150
Zhengzhou, Changsha, Shanghai
2022-08-08
Active, closed
DualityBio Inc.
Phase 1/2
1,123
Bengbu, Hefei, Fuzhou, Lanzhou, Dongguan, Guangzhou, Guigang, Nanning
2022-07-19
Recruiting
Ranok Therapeutics (Hangzhou) Co., Ltd.
Phase 1/2
32
Beijing
2022-07-12
Recruiting
Zhuhai Yufan Biotechnologies Co., Ltd
Phase 1/2
267
Zhengzhou, Chengdu, Hangzhou, Beijing
2022-05-30
Recruiting
A Clinical Study of CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors
NCT05518253Metastatic Tumor, Advanced Solid Tumor, Renal Cell Carcinoma, Ovarian Cancer
Weijia Fang, MD
Phase 1
30
Hangzhou
2022-05-30
Recruiting
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1/2
312
Guangzhou, Zhengzhou
2022-05-25
Recruiting
Keymed Biosciences Co.Ltd
Phase 1/2
248
Chengdu, Shanghai
2022-04-21
Active, closed
Innolake Biopharm
Phase 1
48
Jinan, Shanghai
2022-04-11
Not yet open
Xuanzhu Biopharmaceutical Co., Ltd.
Phase 1
232
Beijing
2022-04
Recruiting
RemeGen Co., Ltd.
Phase 1/2
135
Shanghai, Hangzhou
2022-03-03
Recruiting
Impact Therapeutics, Inc.
Phase 1/2
61
Beijing
2022-02-11
Recruiting
Nanjing Leads Biolabs Co.,Ltd
Phase 1/2
396
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Guanzhou, Nanning
2022-01-06
Recruiting
Shanghai Hansoh Biomedical Co., Ltd
Phase 1
177
Shanghai
2022-01-05
Recruiting
A Clinical Study on TIL for the Treatment of Advanced Solid Tumors
NCT05087745Advanced Solid Tumor, Tumor Infiltrating Lymphocytes, Treatment Side Effects, Effects of Immunotherapy
DrugTumor Infiltrating Lymphocytes
Shanghai Juncell Therapeutics
Early Phase 1
50
Hangzhou
2021-12-10
Recruiting
Akeso
Phase 1/2
198
Hangzhou
2021-11-03
Recruiting
HitGen Inc.
Phase 1
57
Chengdu
2021-10-18
Recruiting
First in Human, Dose Escalation Study of AN4005
NCT04999384Advanced Solid Tumor, Advanced Lymphoma
Adlai Nortye Biopharma Co., Ltd.
Phase 1
31
Beijing, Harbin, Wuhan
2021-09-27
Active, closed
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 1/2
414
Chengdu
2021-09-15
Recruiting
Ascentage Pharma Group Inc.
Phase 1/2
95
Guangzhou, Hangzhou, Shanghai
2021-05-26
Recruiting
Evaluate the Safety and Clinical Activity of HH2853
NCT04390737FL Lymphoma, Epithelioid Sarcoma, Peripheral T Cell Lymphoma, Advanced Solid Tumor
DrugHH2853
Haihe Biopharma Co., Ltd.
Phase 1/2
254
Hefei, Beijing, Guangzhou, Nanning, Zhengzhou, Wuhan, Changsha, Nanjing
2020-09-08
Recruiting
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 1
60
Nanjing
2014-03-19
Rows per page Showing 1–153 of 153
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 9 November 2026. https://priyalifescience.com/clinical-trials-china/condition/advanced-solid-tumor

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,187 studies in total at the last sync on 08 Nov 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 153 of those studies listing the condition Advanced Solid Tumor.

How many Advanced Solid Tumor trials are recruiting in China?

119 of the 153 studies on this page are recruiting new participants as of the 08 Nov 2026, 03:17 UTC sync. A further 12 have not yet opened recruitment, 21 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Advanced Solid Tumor), 153 studies
PhaseStudiesRecruitingShare
Phase 1826953.6%
Phase 1/2554035.9%
Phase 2945.9%
Early Phase 1553.3%
Not applicable110.7%
Observational100.7%

Most active sponsors

Lead sponsors with the most studies (Advanced Solid Tumor)
Lead sponsorStudiesRecruiting
BeOne Medicines1111
Cancer Institute and Hospital, Chinese Academy of Medical Sciences54
Daiichi Sankyo42
LaNova Medicines Limited42
MediLink Therapeutics (Suzhou) Co., Ltd.43
Suzhou Zelgen Biopharmaceuticals Co.,Ltd42
Hansoh BioMedical R&D Company33
Qilu Pharmaceutical Co., Ltd.32
Xuanzhu Biopharmaceutical Co., Ltd.31
Ascentage Pharma Group Inc.22
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.